JO
RGLS

John Overdeck’s Regulus Therapeutics RGLS Stock Holding History

John Overdeck’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,264
Closed -$35.2K – 3447
2024
Q4 		$35.2K Buy
22,264
+3,083
+16% +$4.74K ﹤0.01% 3070
2024
Q3 		$30.1K Sell
19,181
-16,118
-46% -$26.7K ﹤0.01% 3002
2024
Q2 		$63K Buy
+35,299
New +$81.9K ﹤0.01% 2868
2022
Q2 		– Sell
-11,444
Closed -$34K – 2868
2022
Q1 		$34K Buy
11,444
+5,913
+107% +$15.4K ﹤0.01% 2510
2021
Q4 		$17K Buy
+5,531
New +$24.6K ﹤0.01% 4179
2021
Q2 		– Sell
-107,021
Closed -$1.67M – 4484
2021
Q1 		$1.67M Buy
107,021
+104,049
+3,501% +$1.54M ﹤0.01% 1855
2020
Q4 		$40K Buy
+2,972
New +$21.8K ﹤0.01% 3259
2020
Q3 		– Sell
-1,633
Closed -$11K – 3480
2020
Q2 		$11K Buy
+1,633
New +$10.7K ﹤0.01% 2877
2019
Q1 		– Sell
-2,222
Closed -$21K – 3398
2018
Q4 		$21K Buy
+2,222
New +$36.8K ﹤0.01% 2888
2015
Q1 		– Sell
-183
Closed -$351K – 2813
2014
Q4 		$351K Buy
+183
New +$325K ﹤0.01% 1871

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's RGLS Position: Q1 2025 in Review

John Overdeck sold out of Regulus Therapeutics (RGLS) in Q1 2025, closing a stake of 22,264 shares — an estimated $35.2K sold.

John Overdeck first reported a position in RGLS in Q4 2014 and held it in 10 quarters. The position peaked at $1.67M in Q1 2021. 75 funds tracked by Wall St. Rank hold RGLS as of Q1 2025.

  • John Overdeck reported no remaining Regulus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • John Overdeck sold 22,264 Regulus Therapeutics shares in Q1 2025, an estimated $35.2K.
  • John Overdeck first reported a position in Regulus Therapeutics in Q4 2014 and held it in 10 quarters.
  • John Overdeck's Regulus Therapeutics position peaked at $1.67M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.